X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (84798) 84798
Newsletter (19338) 19338
Newspaper Article (3561) 3561
Book Chapter (213) 213
Transcript (195) 195
Magazine Article (182) 182
Dissertation (108) 108
Conference Proceeding (71) 71
Publication (67) 67
Trade Publication Article (25) 25
Book / eBook (22) 22
Book Review (17) 17
Streaming Video (12) 12
Web Resource (11) 11
Reference (10) 10
Government Document (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lung cancer, non-small cell (57235) 57235
humans (51556) 51556
science & technology (47666) 47666
life sciences & biomedicine (45645) 45645
cancer (33831) 33831
oncology (31831) 31831
research (29293) 29293
female (28482) 28482
male (28406) 28406
lung neoplasms - pathology (24389) 24389
middle aged (24275) 24275
lung cancer (23403) 23403
aged (23381) 23381
carcinoma, non-small-cell lung - pathology (22258) 22258
care and treatment (21444) 21444
carcinoma, non-small-cell lung - drug therapy (18704) 18704
lung neoplasms - drug therapy (18327) 18327
oncology, experimental (17425) 17425
non-small cell lung cancer (16038) 16038
lung cancer, small cell (15735) 15735
adult (14696) 14696
prognosis (14310) 14310
chemotherapy (12943) 12943
carcinoma, non-small-cell lung - genetics (12061) 12061
lung neoplasms - genetics (11965) 11965
neoplasm staging (11231) 11231
analysis (9792) 9792
aged, 80 and over (9765) 9765
respiratory system (9729) 9729
metastasis (9649) 9649
lung neoplasms - mortality (9554) 9554
carcinoma, non-small-cell lung - mortality (9398) 9398
genetic aspects (9098) 9098
physical fitness (8681) 8681
treatment outcome (8274) 8274
tumors (8265) 8265
lung neoplasms - metabolism (8150) 8150
carcinoma, non-small-cell lung - metabolism (7987) 7987
non-small cell lung carcinoma (7983) 7983
lung neoplasms - surgery (7077) 7077
carcinoma, non-small-cell lung - surgery (7010) 7010
mutation (6892) 6892
antineoplastic combined chemotherapy protocols - therapeutic use (6779) 6779
health aspects (6691) 6691
cell line, tumor (6686) 6686
surgery (6392) 6392
retrospective studies (6370) 6370
apoptosis (5883) 5883
radiotherapy (5874) 5874
survival rate (5589) 5589
animals (5484) 5484
drug therapy (5347) 5347
cancer therapies (5321) 5321
antineoplastic agents - therapeutic use (5309) 5309
survival analysis (5263) 5263
development and progression (5245) 5245
hematology, oncology and palliative medicine (5226) 5226
clinical trials (5090) 5090
epidermal growth factor (5086) 5086
patients (5025) 5025
medical research (4939) 4939
carcinoma, non-small-cell lung - radiotherapy (4906) 4906
lung neoplasms - therapy (4896) 4896
carcinoma, non-small-cell lung - therapy (4869) 4869
lung neoplasms - radiotherapy (4750) 4750
non-small-cell lung cancer (4465) 4465
nsclc (4462) 4462
respiratory tract diseases (4459) 4459
antineoplastic agents (4435) 4435
abridged index medicus (4417) 4417
gene expression (4262) 4262
antimitotic agents (4242) 4242
immunohistochemistry (4203) 4203
lung neoplasms - diagnosis (4047) 4047
immunotherapy (4034) 4034
carcinoma, non-small-cell lung - diagnosis (3967) 3967
patient outcomes (3878) 3878
biochemistry (3877) 3877
medicine, experimental (3748) 3748
mice (3615) 3615
universities and colleges (3591) 3591
pharmaceutical industry (3566) 3566
proteins (3559) 3559
disease-free survival (3535) 3535
medical prognosis (3527) 3527
follow-up studies (3492) 3492
risk factors (3433) 3433
diagnosis (3301) 3301
pharmacology & pharmacy (3297) 3297
cell biology (3247) 3247
kinases (3212) 3212
carcinoma, non-small-cell lung - secondary (3169) 3169
gene expression regulation, neoplastic (3160) 3160
combined modality therapy (3157) 3157
medicine & public health (3084) 3084
lung neoplasms - diagnostic imaging (3076) 3076
carcinoma, non-small-cell lung - diagnostic imaging (3047) 3047
radiology, nuclear medicine & medical imaging (3034) 3034
adenocarcinoma - pathology (2974) 2974
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (104623) 104623
Chinese (1809) 1809
French (1186) 1186
Japanese (1169) 1169
German (553) 553
Spanish (254) 254
Polish (219) 219
Korean (209) 209
Russian (203) 203
Portuguese (133) 133
Italian (101) 101
Turkish (84) 84
Czech (57) 57
Hungarian (45) 45
Dutch (21) 21
Norwegian (17) 17
Bulgarian (16) 16
Serbian (15) 15
Danish (14) 14
Romanian (13) 13
Croatian (9) 9
Slovak (9) 9
Finnish (8) 8
Icelandic (8) 8
Lithuanian (7) 7
Hebrew (5) 5
Swedish (5) 5
Persian (2) 2
Slovenian (2) 2
Belarusian (1) 1
Bosnian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 11/2014, Volume 371, Issue 21, pp. 1963 - 1971
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2017, Volume 377, Issue 9, pp. 829 - 838
...–small-cell lung cancer. Importantly, it reduced the risk of CNS relapse. 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - secondary | Aged, 80 and over | Adult | Female | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Treatment outcome | Care and treatment | Chemotherapy | Usage | Analysis | Lung cancer, Non-small cell | Drug therapy | Cancer | Epidermal growth factor receptors | Laboratories | Lung cancer | Non-small cell lung carcinoma | Cytotoxicity | Metastasis | Patients | Cancer therapies | Metastases | Pembrolizumab | Hospitals | Platinum | PD-L1 protein | Response rates | Death | Mutation | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
...–small-cell lung cancer (NSCLC), ALK rearrangement occurs in approximately 5% of cases. 2 – 8 ALK -rearranged tumors depend on ALK for growth and survival and show marked sensitivity to ALK inhibitors such as crizotinib... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had similar response rates, but osimertinib... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article